The Hippo Pathway in Prostate Cancer

Area of Science:

• Oncology
• Molecular Biology
• Cancer Research

Background:

• Prostate cancer (PCa) is a leading cancer in men, with limited treatment options for castration-resistant PCa (CRPC).
• The Hippo pathway, regulating cell growth and organ size, and its downstream effectors Yes-associated protein (YAP) and transcriptional co-activator with PDZ-binding motif (TAZ) are crucial in stem cell biology and cancer.
• Dysregulation of the Hippo pathway and YAP/TAZ hyperactivity are observed in various cancers, suggesting their role in tumorigenesis.

Purpose of the Study:

• To review the current understanding of the Hippo pathway, YAP, and TAZ in prostate cancer development and progression.
• To explore the interplay between the Hippo-YAP/TAZ pathway and the androgen receptor (AR) in PCa.
• To identify potential therapeutic strategies targeting the Hippo pathway and YAP/TAZ for CRPC treatment.

Main Methods:

• Literature review synthesizing recent findings on the Hippo pathway, YAP/TAZ, and prostate cancer.
• Analysis of the regulatory mechanisms connecting Hippo-YAP/TAZ signaling with androgen receptor (AR) in PCa.
• Examination of how YAP/TAZ promotes castration resistance through cellular stemness.

Main Results:

• Hyperactivation of YAP/TAZ is implicated in prostate cancer onset and progression.
• The Hippo-YAP/TAZ pathway interacts with the AR signaling axis, a key driver of PCa.
• Uncontrolled YAP/TAZ expression contributes to castration resistance by promoting cancer stem cell characteristics.

Conclusions:

• The Hippo pathway and its effectors YAP/TAZ represent promising therapeutic targets for prostate cancer.
• Targeting YAP/TAZ may offer a novel strategy to overcome castration resistance in PCa.
• Further research into the Hippo-YAP/TAZ pathway could lead to effective treatments for advanced prostate cancer.